Project
Overcoming access challenges to new PrEP options
The Coalition to Accelerate Access to Long-Acting PrEP brings together donors, civil society, ministries of health, implementation science think tanks and partner organizations to ensure an accelerated, equitable, sustainable, and collaborative approach to optimizing access to new long-acting PrEP options. The Coalition is convened by the Global Fund, PEPFAR, Unitaid, UNAIDS and WHO, with AVAC as the Secretariat.
The Coalition’s objective is practical: to coordinate key stakeholder activities on long-acting PrEP access, including jointly developing strategies to identify and overcome access challenges for new PrEP options available now and those in the pipeline.
In 2012, oral PrEP was approved for use as a safe and effective option for HIV prevention. But the field moved too slowly, missing 2020 prevention targets by millions. In 2022, the number of initiated oral PrEP users finally hit three million, but still only a fraction of the estimated number of people who need it and could benefit from it.
As new, longer-acting PrEP options such as injectable cabotegravir and lenacapavir reach the market, the world cannot afford to squander another decade navigating these challenges. This coalition is setting an agenda for bold action, leveraging global urgency, and coordinating partnerships.
Product developers, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play. The Coalition is applying lessons learned from oral PrEP, creating plans to overcome the unique challenges for new prevention options, and ensuring that new, longer-acting PrEP options including injectable CAB and the dapivirine vaginal ring will be available and equitably accessible to all who need them, more quickly than ever before.
Discrete working groups are taking on: Demand assessment; Evaluation of cost and regulatory procedures; Finance and procurement; Demand creation and supportive policies. Each of these working groups involve robust representation from ministries of health and civil society. To extend the reach and impact of this work, the Coalition engages with efforts underway to:
The Coalition provides quarterly updates to chart progress. Visit this page on PrEPWatch for more on the Coalition and its latest updates.
A long-acting PrEP status update is also available, synthesizing the current status of long-acting PrEP products. Visit for graphics pertaining to the regulatory approvals, volumes, ongoing and planned implementation science studies, and non-profit prices for currently available long-acting PrEP products
For more information or with questions for the Coalition co-convenors, contact [email protected].
report
This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir; funders and countries on track for early introduction of injectable lenacapavir; and where new Phase 3 efficacy trials testing MK-8527 are taking place.
infographic
Slides with the current status and proposed priorities for long-acting PrEP products, regulatory approvals, planning & budgeting, delivery, and much more.
infographic
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir.
In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.